{"id":"https://openalex.org/W4406541567","doi":"https://doi.org/10.1158/1078-0432.28227581","title":"Supplementary Table S4 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer","display_name":"Supplementary Table S4 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer","publication_year":2025,"publication_date":"2025-01-17","ids":{"openalex":"https://openalex.org/W4406541567","doi":"https://doi.org/10.1158/1078-0432.28227581"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.28227581","doi":"https://doi.org/10.1158/1078-0432.28227581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.28227581","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109393906","display_name":"Jesus Del Santo Anampa","orcid":"https://orcid.org/0000-0002-1898-180X","observed_orcids":["https://orcid.org/0000-0002-1898-180X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jesus D. Anampa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1898-180X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103397917","display_name":"Daniel Lee Flynn","orcid":"https://orcid.org/0000-0002-3752-7370","observed_orcids":["https://orcid.org/0000-0002-3752-7370"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel L. Flynn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3752-7370","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088727544","display_name":"Cynthia B. Leary","orcid":"https://orcid.org/0009-0009-1980-1434","observed_orcids":["https://orcid.org/0009-0009-1980-1434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Leary","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-1980-1434","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110977800","display_name":"Sun Young Oh","orcid":"https://orcid.org/0009-0005-3197-9180","observed_orcids":["https://orcid.org/0009-0005-3197-9180","https://orcid.org/0009-0008-8132-3771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sun Oh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-3197-9180","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100662163","display_name":"Xiaonan Xue","orcid":"https://orcid.org/0000-0003-2872-8119","observed_orcids":["https://orcid.org/0000-0003-2872-8119"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaonan Xue","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2872-8119","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002393604","display_name":"Maja H. Oktay","orcid":"https://orcid.org/0000-0002-8115-3898","observed_orcids":["https://orcid.org/0000-0002-8115-3898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maja H. Oktay","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8115-3898","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014100567","display_name":"John S. Condeelis","orcid":"https://orcid.org/0000-0001-8826-2336","observed_orcids":["https://orcid.org/0000-0001-8826-2336"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John S. Condeelis","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8826-2336","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5085875361","display_name":"Joseph A. Sparano","orcid":"https://orcid.org/0000-0002-9031-2010","observed_orcids":["https://orcid.org/0000-0002-9031-2010"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph A. Sparano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9031-2010","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.7085000276565552,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.7085000276565552,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.10320000350475311,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.06700000166893005,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rebastinib","display_name":"rebastinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":1.0},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.9679999947547913},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6959999799728394},{"id":"https://openalex.org/keywords/ctcae-grading","display_name":"CTCAE grading","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.98716139793396},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6985580325126648},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6724237203598022},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6642894148826599},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5496484041213989},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.545912504196167},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47813475131988525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46328654885292053},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32796943187713623},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3259667158126831},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.14371663331985474}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.28227581","doi":"https://doi.org/10.1158/1078-0432.28227581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/28227581","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_S4_from_Phase_Ib_Clinical_and_Pharmacodynamic_Study_of_the_TIE2_Kinase_Inhibitor_Rebastinib_with_Paclitaxel_or_Eribulin_in_HER2-Negative_Metastatic_Breast_Cancer/28227581","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.28227581","doi":"https://doi.org/10.1158/1078-0432.28227581","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227581","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2796001254","https://openalex.org/W2416167623","https://openalex.org/W2314283413","https://openalex.org/W2613871272","https://openalex.org/W3153808353","https://openalex.org/W3160156778","https://openalex.org/W2767183100","https://openalex.org/W2613657120","https://openalex.org/W2884577979","https://openalex.org/W2587781731"],"abstract_inverted_index":{"Supplementary":[0],"Table":[1],"S4":[2],"shows":[3],"treatment":[4],"Related":[5],"Adverse":[6],"Events":[7],"(TRAE)":[8],"in":[9],"the":[10],"entire":[11],"study":[12],"(safety":[13],"analysis":[14],"set)":[15],"by":[16],"CTCAE":[17],"grade":[18],"(n":[19],"=":[20],"27).":[21]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2025-10-10T00:00:00"}